Recombinant Human HTATIP2 protein

HTATIP2 (HIV-1 Tat-interacting protein 2), also known as TIP30 or CC3. is a tumor suppressor gene encoding a 30 kDa protein initially identified through its interaction with the HIV-1 Tat protein. This multifunctional protein plays critical roles in apoptosis, angiogenesis inhibition, and metastasis suppression. Structurally, HTATIP2 contains a short-chain dehydrogenase/reductase (SDR) domain and functions as a cofactor-dependent transcription regulator, influencing pathways like NF-κB and STAT3 signaling.

In cancer biology, HTATIP2 is frequently downregulated in various malignancies including hepatocellular carcinoma, breast cancer, and non-small cell lung cancer. Its loss correlates with poor prognosis, enhanced tumor growth, and increased vascularization. Mechanistically, HTATIP2 induces apoptosis through caspase activation while inhibiting angiogenesis by suppressing pro-angiogenic factors like VEGF.

Recombinant HTATIP2 protein, typically produced in E. coli or mammalian expression systems, retains these biological activities. The production process involves cloning the coding sequence into expression vectors, followed by affinity chromatography purification using tags like His-tag. Quality control includes SDS-PAGE, Western blotting, and functional assays to verify apoptosis-inducing and angiogenesis-inhibiting capabilities.

This recombinant protein serves as a vital tool for studying tumor suppression mechanisms, screening anticancer compounds, and developing gene therapies. Current research explores its potential in combination therapies and as a biomarker for cancer progression. The conserved structure across species (human, mouse, rat) facilitates cross-species experimental models, while ongoing studies investigate its epigenetic regulation and interaction networks in tumor microenvironments.